Physician profile
David L Naylor
NPI 1730166844
$16,672.08
in general payments reported to CMS, 2019-2025
61 companies · $2,406 in 2025
The $2,406 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,599 · 2020: $2,202 · 2021: $2,455 · 2022: $2,312 · 2023: $2,421 · 2024: $2,277 · 2025: $2,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,104.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,836.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,628.16 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,466.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,414.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,160.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $985.77 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $782.87 | 2023-2025 | Rexulti |
| Abbott Laboratories | $687.56 | 2019-2025 | Freestyle Libre, Freestyle Libre 3 |
| Astellas Pharma US INC | $622.57 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $539.21 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $457.37 | 2019-2025 | Spravato |
| Allergan, INC. | $407.74 | 2019-2020 | |
| Amarin Pharma, INC. | $399.17 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.47 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $270.53 | 2019-2025 | Trulance, Xifaxan, Relistor |
Show all 60 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150,807.08 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Naylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.